Understanding Afrezza: Mechanism and Place in Therapy

Afrezza is a unique rapid‑acting insulin delivered via oral inhalation. Its active ingredient, insulin human, is absorbed across the alveoli of the lungs, reaching the bloodstream within 12–15 minutes—faster than any injectable mealtime insulin. This pharmacokinetic profile allows Afrezza to mimic the body’s natural first‑phase insulin response, peaking at about 30 minutes and clearing the system within 90 minutes. As a result, post‑meal glucose spikes can be blunted more effectively than with subcutaneously injected insulins such as lispro, aspart, or glulisine. The rapid onset and short duration align closely with the physiological insulin release seen in individuals without diabetes, offering a more dynamic approach to prandial coverage.

Because Afrezza is inhaled and not injected, it eliminates the discomfort, injection anxiety, and site‑related issues (lipodystrophy, scarring) that can accompany traditional insulin therapy. For patients who have struggled with injections or who desire greater flexibility in meal timing, Afrezza offers a practical alternative. However, it is not a substitute for basal insulin in most cases; it is designed exclusively for prandial coverage. Patients with type 1 diabetes or advanced type 2 diabetes will still require a long‑acting insulin (e.g., glargine, degludec) to maintain fasting and between‑meal glucose levels. Understanding this distinction is critical before considering a transition.

Is Afrezza Right for You?

Afrezza is indicated for adults with diabetes mellitus (both type 1 and type 2) to improve glycemic control. It is not approved for pediatric use. Before considering Afrezza, you and your healthcare provider must evaluate several factors beyond just glycemic patterns:

  • Lung health: Afrezza is contraindicated in patients with chronic lung disease such as asthma or COPD, and in those who smoke or have recently quit (within the past 6 months). A baseline spirometry test (FEV1) is required before starting therapy, with periodic monitoring thereafter. Even patients with mild respiratory symptoms require careful assessment.
  • Inhaled medication tolerance: Some users experience a transient cough or throat irritation. While these effects often diminish within weeks, they can be bothersome enough to discontinue therapy. Practicing proper inhalation technique can reduce these side effects.
  • Blood glucose control pattern: Afrezza works best for patients who have pronounced post‑meal hyperglycemia and who are motivated to dose insulin immediately before eating (within 5 minutes). It is less suitable for those who need precise, extended prandial coverage for high‑fat, high‑protein meals, as its duration is shorter than that of injectable rapid‑acting insulins. Patients with highly variable meal timing or inconsistent carbohydrate intake may find the quick onset advantageous.
  • Lifestyle and convenience: Afrezza’s compact inhaler and no‑refrigeration requirement can improve adherence for active individuals. However, the need to replace cartridges before each meal and the possibility of coughing during social settings are factors to discuss.

Your provider will review your medical history, perform a brief pulmonary assessment, and determine whether Afrezza aligns with your lifestyle and treatment goals. Shared decision-making is essential.

Preparing for the Transition

Switching to Afrezza requires deliberate planning to avoid hyperglycemia during the washout of previous medications and to minimize the risk of hypoglycemia once Afrezza is onboard. Below are the key preparatory steps that should be completed at least one week before the start date.

Comprehensive Medication Review

Create a complete list of all current diabetes medications, including dosages and timing:

  • Insulin types (rapid‑acting, short‑acting, intermediate‑acting, long‑acting, and premixed formulations)
  • Oral antihyperglycemic agents (metformin, sulfonylureas, meglitinides, DPP‑4 inhibitors, SGLT2 inhibitors, GLP‑1 receptor agonists, thiazolidinediones)
  • Non‑insulin injectables (pramlintide, GLP‑1 RAs)
  • Any over‑the‑counter supplements or herbal remedies that affect blood glucose

Your healthcare provider will decide which agents to taper or stop and which to continue. For example, sulfonylureas and meglitinides stimulate endogenous insulin secretion; keeping them alongside mealtime Afrezza could increase hypoglycemia risk. Conversely, metformin or SGLT2 inhibitors often remain unchanged because they act through different mechanisms. Never abruptly discontinue any medication without explicit instruction from your provider.

Pulmonary Assessment

Before your first dose of Afrezza, you must undergo spirometry to measure forced expiratory volume in one second (FEV1). The U.S. prescribing information mandates a baseline FEV1 ≥ 70% of predicted. If FEV1 is below this threshold or if you have a history of reactive airway disease, Afrezza is not recommended. Follow‑up spirometry is typically performed after the first month, then every six months thereafter. Any significant drop in FEV1 (≥15%) warrants discontinuation. Patients with a history of mild intermittent asthma may be eligible after a detailed evaluation, but most will be advised against using inhaled insulin.

Establishing Baseline Monitoring

Begin logging blood glucose readings at least 4–6 times per day for one week before the transition date. Include fasting, pre‑meal, two‑hour post‑meal, and bedtime readings. This data helps your provider set appropriate starting doses and identify the pattern of your glucose excursions. A continuous glucose monitor (CGM) can provide even richer data, especially for detecting post‑prandial peaks and hypoglycemic events. Share these logs with your provider during the pre‑transition visit.

Step‑by‑Step Transition Protocol

The transition from other diabetes medications to Afrezza should be conducted under close medical supervision. The following sequence reflects current clinical practice recommendations and should be tailored to your specific regimen.

Starting Afrezza: Dose Initiation and Titration

Afrezza is supplied as inhalation cartridges in 4, 8, and 12 unit strengths (each cartridge represents a dose of approximately 4, 8, or 12 units of insulin activity, respectively, but the labeling is not directly equivalent to injectable units). Initial dose: For patients previously on mealtime insulin, the starting Afrezza dose is often 50–70% of their usual rapid‑acting injectable dose, split over pre‑meal administration. For those who were not on mealtime insulin (e.g., type 2 patients on oral agents alone), the starting dose is typically 4 units at the largest meal, then titrated upward. The lower starting point reduces the risk of hypoglycemia during the adjustment period.

Titration is guided by post‑meal glucose readings taken 2 hours after the start of the meal. Target increments are usually 4 units per meal per week until the post‑meal glucose falls within the desired range (e.g., <180 mg/dL). Because Afrezza’s effect is short, a second dose (or “correction”) may be needed 2–3 hours after a meal if glucose remains elevated. Patients should be taught to use a correction dose of 4–8 units based on glucose level and meal size. Always confirm with a fingerstick before repeating a dose.

Discontinuing Other Insulins and Oral Agents

  • Rapid‑acting insulin (lispro, aspart, glulisine): Stop immediately on the day you begin Afrezza. Do not overlap; the combination could cause severe hypoglycemia. The last rapid‑acting injection should be given the evening before the transition, provided there is a gap of at least 4 hours before the first Afrezza dose.
  • Short‑acting (regular) insulin: Discontinue at the same time, as it is also used for meal coverage. Regular insulin has a longer duration, so precautions against stacking are especially important.
  • Premixed insulin (e.g., 70/30): Replace the prandial component with Afrezza, but the basal component must be supplied separately (e.g., by a long‑acting insulin). Typically, patients stop the premixed product and start a basal insulin at 50–60% of the total daily insulin dose from the premixed formula, plus Afrezza for meals. The basal dose is then adjusted based on fasting glucose readings.
  • Oral secretagogues (sulfonylureas, meglitinides): These are often reduced by 50% at the start of Afrezza, then discontinued over 2–4 weeks if glucose control remains adequate. Hypoglycemia is the main concern, especially in patients with renal impairment or missed meals. Some providers may discontinue secretagogues entirely on day one if the patient is starting a full Afrezza regimen.
  • Other non‑insulin agents: Metformin, SGLT2 inhibitors, DPP‑4 inhibitors, and GLP‑1 RAs are usually continued unless contraindicated. However, SGLT2 inhibitors combined with Afrezza can increase the risk of euglycemic diabetic ketoacidosis (DKA), so providers may monitor ketones closely, especially in type 1 diabetes.

Integrating Meal Timing and Carbohydrate Counting

Afrezza should be taken at the start of each meal—literally just before the first bite. Its fast onset means you should not wait 15–20 minutes as with some injectable insulins. Carbohydrate counting is still useful for dose determination, although many users find they can rely on meal‑size categories (small, medium, large) once patterns are established. Because Afrezza’s duration is short, consider splitting high‑carb or high‑fat meals into two smaller Afrezza doses (one before the meal, one an hour later) to avoid late post‑prandial hyperglycemia. For meals lasting more than 30 minutes, a split dose may also be beneficial.

Monitoring During the Transition Period

The first 2–4 weeks are critical. Frequent monitoring helps you and your provider fine‑tune doses and detect problems early. Use a structured log that includes blood glucose readings, meal descriptions, Afrezza doses, and any symptoms.

Blood Glucose Targets

Standard glycemic targets apply: fasting <130 mg/dL, post‑meal (2‑hour) <180 mg/dL, and bedtime 120–150 mg/dL. However, during the transition your provider may set slightly higher initial targets to minimize hypoglycemia, especially if you were previously on high doses of insulin or secretagogues. As stability improves, these targets can be tightened. For type 1 diabetes, also monitor for ketones if glucose exceeds 240 mg/dL for more than a few hours, especially if basal insulin is suboptimal.

Recognizing and Managing Hypoglycemia

Because Afrezza is rapid and short, hypoglycemia from it tends to occur within the first 2 hours after dosing. Symptoms (shakiness, sweating, confusion) appear quickly and can escalate. Treatment remains the same: consume 15–20 grams of fast‑acting glucose (tablets, juice) and re‑check in 15 minutes. Always carry a glucagon kit if you take insulin. Educate family and coworkers on how to use it. The short duration of Afrezza means that hypoglycemia from it is often easier to reverse than hypoglycemia from longer‑acting insulins, but because the onset is abrupt, rapid action is still critical.

If you experience nocturnal hypoglycemia, review your evening Afrezza dose—it may be too high for your dinner size, or you may need a bedtime snack. Unlike basal insulin, Afrezza does not cover overnight glucose needs, so a separate basal insulin regimen is essential for type 1 diabetes. Nocturnal lows can also occur if the basal dose is too high, so discuss any nighttime patterns with your provider.

Tracking Side Effects: Cough, Throat Irritation, Lung Function

A mild cough occurs in up to 25% of users during the first few weeks. It often settles without intervention. If it persists or worsens, or if you develop new wheezing, chest tightness, or dyspnea, contact your provider immediately. Spirometry will be repeated; a ≥15% decline in FEV1 is a reason to discontinue Afrezza. Some patients report a metallic taste or hoarseness; these are usually benign and fade with time. Using the inhaler properly—keeping it upright, exhaling fully before use, and inhaling deeply and steadily—can minimize irritation.

Special Considerations for Different Patient Groups

Type 1 Diabetes

Patients with type 1 diabetes require a basal insulin. When transitioning, the basal dose (e.g., glargine or degludec) is typically initiated at 0.3–0.5 units/kg/day, adjusted to achieve stable fasting and pre‑meal glucose. Afrezza covers all meals and snacks. Some type 1 users find they need less basal insulin because Afrezza’s early peak helps reduce hepatic glucose output, but this varies. Never omit the basal insulin; doing so can precipitate diabetic ketoacidosis. Frequent monitoring of ketones during the first week is recommended, especially if glucose runs high.

Type 2 Diabetes on Multiple Oral Agents

For type 2 patients, Afrezza may allow simplification of the regimen. If you are on a sulfonylurea and an SGLT2 inhibitor, for example, the risk of hypoglycemia rises when Afrezza is started. Your provider may halve the sulfonylurea dose and reintroduce it later if needed. In contrast, metformin and GLP‑1 RAs complement Afrezza well—metformin suppresses hepatic glucose production, and GLP‑1 RAs slow gastric emptying, blunting an overshoot of post‑meal glucose that Afrezza might not fully cover. Some patients can eventually discontinue secretagogues entirely, relying solely on Afrezza plus their basal regimen.

Patients with Renal Impairment

Afrezza is not cleared renally; its clearance depends on lung function. Therefore, no dose adjustment is required for chronic kidney disease. However, patients with renal impairment often have reduced insulin clearance from endogenous sources, and their dose requirements may be lower. Close monitoring is warranted, especially during the transition. Additionally, because many oral agents (e.g., metformin, sulfonylureas) require dose adjustments in CKD, a comprehensive medication review is even more critical.

Pregnancy and Lactation

Afrezza is not approved for use during pregnancy or lactation. Pregnant women with diabetes should continue using standard injectable insulins, which have well‑established safety profiles. If a patient becomes pregnant while using Afrezza, they should switch back to injectable insulin under medical guidance.

Common Challenges and How to Overcome Them

  • Persistent cough: Try drinking a sip of water before and after inhalation. If cough continues after 2 weeks, consider a different inhalation technique (slower, deeper breath) or a lower dose. If unresponsive, Afrezza may not be suitable.
  • Post‑meal hyperglycemia after high‑fat meals: These meals cause a delayed glucose peak. Consider splitting your Afrezza dose—take the first half at the meal start and the second half 45–60 minutes later. Alternatively, consider a small additional dose 2 hours after the meal.
  • Inconsistent dose from cartridge: Rarely, a cartridge may not deliver the full dose. Use a new cartridge from a different blister pack. If the problem repeats, report to the manufacturer and consider switching back to injectable insulin temporarily.
  • Hypoglycemia from overlapping doses: Because Afrezza acts so quickly, never “stack” doses for a correction within 2 hours of a meal dose. Use a confirmatory fingerstick before any additional Afrezza. If you need correction, wait at least 2 hours after the last dose.
  • Patient reluctance to discontinue old insulin: Some patients feel “safer” continuing their basal or rapid‑acting insulin while starting Afrezza. This is dangerous and should be strongly discouraged by the care team. Educate patients on the increased risk of severe hypoglycemia and provide a written schedule.
  • Forgetting to dose: Because Afrezza must be taken at the start of each meal, patients may forget if they are not in the habit. Setting a phone alarm or using a pillbox‑style reminder can help. Some patients keep the inhaler at the dining table.

Conclusion

Transitioning to Afrezza offers a new way to manage post‑meal glucose with speed and convenience, but it is not a decision to be taken lightly. A safe switch requires a thorough assessment of lung health, a careful review and adjustment of your current diabetes medications, rigorous blood glucose monitoring, and ongoing communication with your healthcare provider. When executed properly, Afrezza can reduce injection burden, improve meal‑time flexibility, and help you achieve tighter glycemic control. The key is to follow a structured protocol, monitor closely, and address challenges early. With the right preparation and support, many patients find Afrezza a valuable addition to their diabetes management toolkit.

For more information, consult the full prescribing information for Afrezza (FDA), the American Diabetes Association Standards of Medical Care in Diabetes, and Endocrine Society Clinical Practice Guidelines. Additional resources include the manufacturer’s patient support page which offers instructional videos and dosing tools. Always follow your provider’s individualized plan and report any concerning symptoms without delay.